Categories AlphaGraphs, Earnings, Technology
Earnings: Hewlett Packard Enterprise (HPE) Q4 earnings beat Street view
Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) Tuesday reported higher earnings and revenues for the fourth quarter of 2022. The bottom line also exceeded analysts’ forecasts.
Fourth-quarter profit, excluding one-off items, moved up to $0.57 per share from $0.52 per share a year earlier and came in above consensus estimates. On a reported basis, it was a net loss of $304 million or $0.23 per share in the three-month period, compared to a profit of $2.55 billion or $1.91 per share in the same period of 2021.
Check this space to read management/analysts’ comments on Hewlett Packard’s Q4 2022 results
The tech firm’s revenues increased 7% annually to $7.9 billion in the fourth quarter, beating analysts’ estimates. The management also provided guidance for the first quarter and full year of 2023.
“HPE had an impressive fourth quarter, generating an outstanding performance across our key performance metrics. We are producing strong financial results as we meet new customer needs with the edge-to-cloud portfolio that only we can deliver,” said Hewlett Packard’s CEO Antonio Neri.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications